SG10202104876SA - Sgc stimulators - Google Patents
Sgc stimulatorsInfo
- Publication number
- SG10202104876SA SG10202104876SA SG10202104876SA SG10202104876SA SG10202104876SA SG 10202104876S A SG10202104876S A SG 10202104876SA SG 10202104876S A SG10202104876S A SG 10202104876SA SG 10202104876S A SG10202104876S A SG 10202104876SA SG 10202104876S A SG10202104876S A SG 10202104876SA
- Authority
- SG
- Singapore
- Prior art keywords
- sgc stimulators
- sgc
- stimulators
- Prior art date
Links
- 229940127296 soluble guanylate cyclase stimulator Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662419086P | 2016-11-08 | 2016-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202104876SA true SG10202104876SA (en) | 2021-06-29 |
Family
ID=60473639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202104876SA SG10202104876SA (en) | 2016-11-08 | 2017-11-07 | Sgc stimulators |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11180493B2 (en) |
| EP (1) | EP3538520A2 (en) |
| JP (1) | JP7199364B2 (en) |
| CN (1) | CN110267949A (en) |
| AU (1) | AU2017356887B2 (en) |
| CA (1) | CA3042713A1 (en) |
| IL (1) | IL266372B2 (en) |
| MA (1) | MA46755A (en) |
| PH (1) | PH12019501017A1 (en) |
| SG (1) | SG10202104876SA (en) |
| WO (1) | WO2018089330A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3538520A2 (en) * | 2016-11-08 | 2019-09-18 | Cyclerion Therapeutics, Inc. | Sgc stimulators |
| CN108727340B (en) | 2017-04-11 | 2020-12-29 | 广东东阳光药业有限公司 | Fluorine substituted indazoles and use thereof |
| KR20210031931A (en) * | 2018-07-11 | 2021-03-23 | 사이클리온 테라퓨틱스, 인크. | Use of sGC stimulants for the treatment of mitochondrial disorders |
| CN110305125B (en) * | 2019-06-06 | 2021-09-03 | 山东新华制药股份有限公司 | 5-pyrimidine-6-oxy-pyrazolopyridine derivative and preparation method and application thereof |
| CN110669045A (en) * | 2019-09-05 | 2020-01-10 | 南通大学 | 1-methyl- [1,5-a ] -pyridylimidazole-3-nitrile and chemical synthesis method thereof |
| WO2023148203A1 (en) | 2022-02-01 | 2023-08-10 | Charité - Universitätsmedizin Berlin | A soluble guanylat cyclase activator for treating chronic vascular dysfunction |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
| US4203440A (en) | 1978-10-23 | 1980-05-20 | Alza Corporation | Device having variable volume chamber for dispensing useful agent |
| US4627850A (en) | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
| EP0192963B1 (en) | 1985-02-27 | 1988-07-20 | Werkzeugmaschinenfabrik Oerlikon-Bührle AG | Apparatus for measuring the vibrations of a spiral bevel gear transmission in a gear-testing machine |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5324280A (en) | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
| US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
| JP2928079B2 (en) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | 1- (Substituted benzyl) -3- (substituted aryl) condensed pyrazoles, their production and use |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| DE19744026A1 (en) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazole derivatives, their preparation and their use in medicinal products |
| DE19830430A1 (en) | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | New sulfur-substituted sulfonylamino-carboxylic acid N-arylamide derivatives useful as guanylate cyclase activators in treatment of e.g. cardiovascular disorders, asthma and diabetes |
| CZ302691B6 (en) | 1998-07-08 | 2011-09-07 | Sanofi - Aventis Deutschland GmbH | N-arylamide compound, process for its preparation, pharmaceutical composition containing thereof, the compound for use as activator and for use in therapy or prophylaxis |
| DE19834044A1 (en) | 1998-07-29 | 2000-02-03 | Bayer Ag | New substituted pyrazole derivatives |
| DE19834047A1 (en) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituted pyrazole derivatives |
| GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| IL143691A0 (en) | 1998-12-17 | 2002-04-21 | Alza Corp | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
| US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| DE19942809A1 (en) | 1999-09-08 | 2001-03-15 | Bayer Ag | Process for the preparation of substituted pyrimidine derivatives |
| DE19943635A1 (en) | 1999-09-13 | 2001-03-15 | Bayer Ag | Novel aminodicarboxylic acid derivatives with pharmaceutical properties |
| DE10216145A1 (en) | 2002-04-12 | 2003-10-23 | Bayer Ag | Use of stimulators of soluble guanylate cyclase to produce a medicament for treating glaucoma |
| DE10220570A1 (en) * | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamate-substituted pyrazolopyridines |
| DE10232572A1 (en) | 2002-07-18 | 2004-02-05 | Bayer Ag | New 2,5-disubstituted pyrimidine derivatives |
| MXPA06001506A (en) | 2003-08-04 | 2006-05-15 | Pfizer Prod Inc | Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors. |
| DE102006020327A1 (en) * | 2006-04-27 | 2007-12-27 | Bayer Healthcare Ag | Heterocyclic substituted, fused pyrazole derivatives and their use |
| AU2008296974B2 (en) | 2007-09-06 | 2013-10-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| EP2244575B1 (en) | 2008-01-24 | 2013-07-17 | Merck Sharp & Dohme Corp. | Angiotensin ii receptor antagonists |
| US8741910B2 (en) | 2008-11-25 | 2014-06-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| BRPI1008793A2 (en) | 2009-02-26 | 2016-03-08 | Merck Sharp & Dohme | compound use of a compound and pharmaceutical composition |
| US9284301B2 (en) | 2010-03-25 | 2016-03-15 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| US9365574B2 (en) | 2010-05-27 | 2016-06-14 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| US8895583B2 (en) | 2010-10-28 | 2014-11-25 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| CA2847075A1 (en) | 2011-09-02 | 2013-03-07 | Bayer Intellectual Property Gmbh | Substituted annellated pyrimidine and the use thereof |
| EP2933248B1 (en) | 2012-09-14 | 2018-01-31 | Mitsubishi Tanabe Pharma Corporation | Novel renin inhibitor |
| LT2970243T (en) | 2013-03-15 | 2020-03-10 | Cyclerion Therapeutics, Inc. | Sgc stimulators |
| CN105764893A (en) | 2013-10-30 | 2016-07-13 | 拜耳制药股份公司 | Heteroaryl substituted pyrazoles |
| EA201891416A1 (en) * | 2015-12-14 | 2018-12-28 | Айронвуд Фармасьютикалз, Инк. | APPLICATION of sGC STIMULATORS FOR THE TREATMENT OF GASTRIC AND INTESTINAL SPINKLIN TREATMENT |
| WO2017108441A1 (en) | 2015-12-22 | 2017-06-29 | Universiteit Maastricht | Treatment of cognitive impairment with cgc stimulator |
| WO2017121700A1 (en) | 2016-01-15 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | 1,3-disubstituted 1h-pyrazolo[3,4-b]pyridine derivatives and use thereof as stimulators of soluble guanylate cyclase |
| US11690828B2 (en) * | 2016-11-08 | 2023-07-04 | Cyclerion Therapeutics, Inc. | Treatment of CNS diseases with sGC stimulators |
| EP3538520A2 (en) * | 2016-11-08 | 2019-09-18 | Cyclerion Therapeutics, Inc. | Sgc stimulators |
-
2017
- 2017-11-07 EP EP17804735.3A patent/EP3538520A2/en active Pending
- 2017-11-07 IL IL266372A patent/IL266372B2/en unknown
- 2017-11-07 SG SG10202104876SA patent/SG10202104876SA/en unknown
- 2017-11-07 US US16/348,377 patent/US11180493B2/en active Active
- 2017-11-07 CN CN201780081092.2A patent/CN110267949A/en active Pending
- 2017-11-07 WO PCT/US2017/060305 patent/WO2018089330A2/en unknown
- 2017-11-07 CA CA3042713A patent/CA3042713A1/en active Pending
- 2017-11-07 JP JP2019545725A patent/JP7199364B2/en active Active
- 2017-11-07 MA MA046755A patent/MA46755A/en unknown
- 2017-11-07 AU AU2017356887A patent/AU2017356887B2/en not_active Ceased
-
2019
- 2019-05-08 PH PH12019501017A patent/PH12019501017A1/en unknown
-
2021
- 2021-09-27 US US17/485,858 patent/US20220017515A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017356887B2 (en) | 2022-06-30 |
| EP3538520A2 (en) | 2019-09-18 |
| IL266372B1 (en) | 2023-07-01 |
| IL266372B2 (en) | 2023-11-01 |
| JP7199364B2 (en) | 2023-01-05 |
| AU2017356887A8 (en) | 2019-06-06 |
| IL266372A (en) | 2019-06-30 |
| US11180493B2 (en) | 2021-11-23 |
| CN110267949A (en) | 2019-09-20 |
| WO2018089330A8 (en) | 2019-03-28 |
| WO2018089330A3 (en) | 2018-06-28 |
| WO2018089330A2 (en) | 2018-05-17 |
| MA46755A (en) | 2021-06-02 |
| JP2020500215A (en) | 2020-01-09 |
| US20200071318A1 (en) | 2020-03-05 |
| US20220017515A1 (en) | 2022-01-20 |
| CA3042713A1 (en) | 2018-05-17 |
| AU2017356887A1 (en) | 2019-05-23 |
| PH12019501017A1 (en) | 2019-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL251113A0 (en) | Sgc stimulators | |
| GB201820152D0 (en) | Autonomous-behaviour-type robot | |
| AU201615901S (en) | Robot | |
| IL269812A (en) | Ferroportin-inhibitor salts | |
| AU201616677S (en) | Cylindres | |
| GB2550864B (en) | Well | |
| IL290338A (en) | Solid dispersions comprising a sgc stimulator | |
| IL251115A0 (en) | Sgc stimulators | |
| IL275415A (en) | Sgc stimulators | |
| IL266372A (en) | Sgc stimulators | |
| HUE045423T2 (en) | Implantable assembly | |
| PL3216505T3 (en) | Playmat | |
| DK3470112T3 (en) | Cochlear implantat | |
| GB201703128D0 (en) | Kraftfahrzeugkarosserie | |
| GB2567279B (en) | Salts | |
| IL259649B (en) | Sterility-preserving robotic frontend-system | |
| AU201711700S (en) | Electro-muscular stimulator | |
| AU201711699S (en) | Electro-muscular stimulator | |
| GB201703980D0 (en) | Manipulator | |
| AU2016361V (en) | JCU8 Desmanthus virgatus | |
| AU2016360V (en) | JCU7 Desmanthus leptophyllus | |
| AU2016359V (en) | JCU6 Desmanthus bicornutus | |
| AU201616673S (en) | tallboy | |
| AU2016303V (en) | Desse1601 Desmanthus virgatus | |
| GB201614090D0 (en) | Robot |